Cytek Biosciences (CTKB): Evaluating Valuation After TIME's Growth Leaders 2026 Recognition

Cytek Biosciences (CTKB) is catching fresh attention after being named to TIME’s 2026 list of America’s Growth Leaders, a recognition that highlights the company’s momentum and strengths in cell analysis technology.

See our latest analysis for Cytek Biosciences.

After a standout mention on TIME's Growth Leaders list, Cytek’s share price has surged, up 39% in the last month and 35% over the past quarter, as excitement builds around its innovative tech and recognition is fueling fresh momentum. But stepping back, the one-year total shareholder return remains negative, reflecting the bumpy road the stock has traveled even as sentiment shifts on the back of recent news and guidance updates.

If spotlights on biotech breakthroughs have your attention, now's the moment to find other innovators shaping healthcare—explore See the full list for free..

With Wall Street’s attention now firmly fixed on Cytek, the question is whether shares remain undervalued in spite of the buzz, or if recent gains suggest investors have already priced in the next stage of growth.

Most Popular Narrative: 7% Overvalued

With Cytek Biosciences closing at $5.50, the most followed narrative sets fair value at $5.13, suggesting the stock price is running ahead of consensus assumptions. This gap focuses attention on whether growth expectations can keep up with the market's optimism and recent momentum.

Broader adoption of advanced flow cytometry for personalized medicine, immunotherapy, and complex disease research, driven by secular healthcare R&D investment and rising demand for high-dimensional single-cell analysis, positions Cytek's technology at the forefront of multi-year industry growth. This supports sustained top-line expansion.

Read the complete narrative.

Curious what really drives these valuations? The secret sauce in this narrative is a bold top-line growth assumption plus a profit margin transformation that goes well beyond today's numbers. Exposure to global healthcare demand and next-gen cell analysis could change Cytek’s outlook if these forecasts come true. Will analyst convictions hold up? Unlock the details in the full breakdown.

Result: Fair Value of $5.13 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing weakness in instrument sales and tough competition from larger players could dampen Cytek's growth if these headwinds persist.

Find out about the key risks to this Cytek Biosciences narrative.

Build Your Own Cytek Biosciences Narrative

If you see the story unfolding differently or want to dig into the numbers yourself, it's quick and easy to create your own view from scratch. Do it your way.

A great starting point for your Cytek Biosciences research is our analysis highlighting 1 important warning sign that could impact your investment decision.

Unlock More Winning Ideas

Don’t just stick with the obvious picks. Your next big opportunity is waiting if you check what's possible with the Simply Wall Street Screener.

• Tap into growth stories by seeking out these 886 undervalued stocks based on cash flows and catch the companies flying under Wall Street’s radar.
• Spot emerging trends early by jumping into these 25 AI penny stocks transforming industries with breakthrough artificial intelligence.
• Boost your income potential by adding these 16 dividend stocks with yields > 3% offering yields above 3% right now to your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com